Justin A. Clark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Justin A. Clark has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- David S. Burgess
Department of Pharmacy Practice and Science University of Kentucky College of Pharmacy Lexington Kentucky USA
9 shared publications Brandon Kulengowski
University of Kentucky College of Pharmacy, Lexington, KY, USA; Albert B. Chandler Hospital, UK Healthcare, Lexington, KY, USA
1 shared publication- Brandon Kulengowski
Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, USA
1 shared publication Daniela C. Moga
College of Pharmacy, University of Kentucky, Lexington, KY, USA
1 shared publicationDaniella Moga
University of Kentucky , Lexington, Kentucky
1 shared publicationDonna R Burgess
UK HealthCare , Lexington, KY
1 shared publication
Latest Publications
- Open Access
- 25 October 2024
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e189
The effect of carbapenem-resistant versus carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
Objective: We sought to compare patient outcomes between carbapenem-resistant Enterobacterales (CRE) and carbapenem-susceptible Enterobacterales (CSE) infections at our academic medical center. Design: We conducted a retrospective cohort study of adult patients with a positive culture of E. coli, E. cloacae, K. aerogenes, K. oxytoca, and/or K. pneumoniae admitted at UK HealthCare (January 1, 2010–December 31, 2019). Based on the type of pathogen on the date of the first culture (index date), patients were included in the CRE (i.e., exposed) group, or the CSE (comparator) group. Exclusion criteria were age < 18 years old, pregnancy, endocarditis, osteomyelitis, necrotizing fasciitis, or cystic fibrosis. We evaluated the impact of CRE vs CSE on a composite outcome of 30-day of all-cause mortality or discharge to hospice using Kaplan–Meier survival curves and Cox proportional hazard regression with inverse probability of treatment weights (IPTW). Results: Of 17,839 hospitalized patients, 128 and 6,953 patients were included in the CRE and CSE groups, respectively. Baseline differences existed in sex-assigned-at-birth, admission source, time-to-index culture, and infection type/severity. Most CRE index cultures observed (76%) only exhibited resistance to ertapenem. IPTW-adjusted HR [95% CI] of composite outcome was 0.99 [0.65, 1.51] after 30 days. Follow-up analysis in patients with carbapenem-non-susceptible Enterobacteralesbloodstream infections on index yielded an HR of 1.38 [0.85, 2.24]. Conclusions: Risk of composite outcome was not estimated to differ between patients with CRE and CSE in the overall analysis. Although follow-up analysis identified an increased risk, we cannot statistically distinguish this from a null effect.
- 25 October 2024
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e189
Open AccessThe effect of carbapenem-resistant versus carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
Objective: We sought to compare patient outcomes between carbapenem-resistant Enterobacterales (CRE) and carbapenem-susceptible Enterobacterales (CSE) infections at our academic medical center. Design: We conducted a retrospective cohort study of adult patients with a positive culture of E. coli, E. cloacae, K. aerogenes, K. oxytoca, and/or K. pneumoniae admitted at UK HealthCare (January 1, 2010–December 31, 2019). Based on the type of pathogen on the date of the first culture (index date), patients were included in the CRE (i.e., exposed) group, or the CSE (comparator) group. Exclusion criteria were age < 18 years old, pregnancy, endocarditis, osteomyelitis, necrotizing fasciitis, or cystic fibrosis. We evaluated the impact of CRE vs CSE on a composite outcome of 30-day of all-cause mortality or discharge to hospice using Kaplan–Meier survival curves and Cox proportional hazard regression with inverse probability of treatment weights (IPTW). Results: Of 17,839 hospitalized patients, 128 and 6,953 patients were included in the CRE and CSE groups, respectively. Baseline differences existed in sex-assigned-at-birth, admission source, time-to-index culture, and infection type/severity. Most CRE index cultures observed (76%) only exhibited resistance to ertapenem. IPTW-adjusted HR [95% CI] of composite outcome was 0.99 [0.65, 1.51] after 30 days. Follow-up analysis in patients with carbapenem-non-susceptible Enterobacteralesbloodstream infections on index yielded an HR of 1.38 [0.85, 2.24]. Conclusions: Risk of composite outcome was not estimated to differ between patients with CRE and CSE in the overall analysis. Although follow-up analysis identified an increased risk, we cannot statistically distinguish this from a null effect.
- Open Access
- 3 October 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (10) , e0387623
Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides against VIM-producing Enterobacteriaceae
Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections continue to pose a serious threat to healthcare. Due to their unique active site, MBLs evade the activity of many novel beta-lactam/beta-lactamase inhibitor combinations, which have been specifically targeted toward those carbapenemases with serine active sites. Furthermore, resistance to most, if not all, other clinically relevant antimicrobial classes leaves few reliable therapeutic options. Combination therapy has thus played a vital role in the treatment of MBL-producing CRE infections. In this study, we utilized the static time-kill assay to investigate clinically relevant concentrations of cefepime, piperacillin-tazobactam, and meropenem alone and in combination with either amikacin or the novel plazomicin to determine if combinations of routinely used beta-lactam therapy with an aminoglycoside would achieve bactericidal activity against eight clinically isolated Verona integron-encoded MBL (VIM)-producing CRE. Furthermore, we compared this activity to the combination of aztreonam/avibactam, which has shown potent activity against MBL-producing CRE. Both aztreonam/avibactam and meropenem with either aminoglycoside were rapidly bactericidal within 4 hours and remained bactericidal through 24 hours against all isolates with few exceptions. Combinations including cefepime and piperacillin-tazobactam were also rapidly bactericidal, but activity after 24 hours was inconsistent depending upon the partner aminoglycoside and isolate. Further investigation is warranted to elucidate optimal antibiotic exposures against MBL-producing CRE, including novel agents in the pipeline. IMPORTANCE: Carbapenem-resistant Enterobacterales (CRE) are one of the most pressing antimicrobial-resistant threats at present. In addition to exhibiting resistance to many, if not all, commonly used antimicrobial agents, CRE achieves these resistant phenotypes through a variety of mechanisms, each of which can uniquely affect available treatment options. The present study is an in vitro investigation of several Verona integron-encoded metallo-beta-lactamase (VIM)-producing CRE isolated from patients at our academic medical center. Because metallo-beta-lactamases (MBLs) are inherently resistant to many of the novel treatments designed to treat CRE due to their different active site composition, we tested several antimicrobial combinations containing routinely utilized broad-spectrum beta-lactams and aminoglycosides. Our results further our understanding of combination therapy options against VIM-producing CRE, including with non-carbapenem-beta-lactams cefepime and piperacillin. By optimizing combinations of existing antimicrobial agents, we hope to expand the available armamentarium against these resistant pathogens.
- 3 October 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (10) , e0387623
Open AccessComparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides against VIM-producing Enterobacteriaceae
Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections continue to pose a serious threat to healthcare. Due to their unique active site, MBLs evade the activity of many novel beta-lactam/beta-lactamase inhibitor combinations, which have been specifically targeted toward those carbapenemases with serine active sites. Furthermore, resistance to most, if not all, other clinically relevant antimicrobial classes leaves few reliable therapeutic options. Combination therapy has thus played a vital role in the treatment of MBL-producing CRE infections. In this study, we utilized the static time-kill assay to investigate clinically relevant concentrations of cefepime, piperacillin-tazobactam, and meropenem alone and in combination with either amikacin or the novel plazomicin to determine if combinations of routinely used beta-lactam therapy with an aminoglycoside would achieve bactericidal activity against eight clinically isolated Verona integron-encoded MBL (VIM)-producing CRE. Furthermore, we compared this activity to the combination of aztreonam/avibactam, which has shown potent activity against MBL-producing CRE. Both aztreonam/avibactam and meropenem with either aminoglycoside were rapidly bactericidal within 4 hours and remained bactericidal through 24 hours against all isolates with few exceptions. Combinations including cefepime and piperacillin-tazobactam were also rapidly bactericidal, but activity after 24 hours was inconsistent depending upon the partner aminoglycoside and isolate. Further investigation is warranted to elucidate optimal antibiotic exposures against MBL-producing CRE, including novel agents in the pipeline. IMPORTANCE: Carbapenem-resistant Enterobacterales (CRE) are one of the most pressing antimicrobial-resistant threats at present. In addition to exhibiting resistance to many, if not all, commonly used antimicrobial agents, CRE achieves these resistant phenotypes through a variety of mechanisms, each of which can uniquely affect available treatment options. The present study is an in vitro investigation of several Verona integron-encoded metallo-beta-lactamase (VIM)-producing CRE isolated from patients at our academic medical center. Because metallo-beta-lactamases (MBLs) are inherently resistant to many of the novel treatments designed to treat CRE due to their different active site composition, we tested several antimicrobial combinations containing routinely utilized broad-spectrum beta-lactams and aminoglycosides. Our results further our understanding of combination therapy options against VIM-producing CRE, including with non-carbapenem-beta-lactams cefepime and piperacillin. By optimizing combinations of existing antimicrobial agents, we hope to expand the available armamentarium against these resistant pathogens.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2536. Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides and aztreonam/avibactam against 8 VIM-producing CRE
Treatment of infections caused by CRE often involves beta-lactam-containing combination therapy, either with a beta-lactamase inhibitor or an agent from a different antimicrobial class. We sought to investigate the activity of several beta-lactam combinations against 8 VIM-producing CRE cultured from patients at our academic medical center using a time-kill assay. Broth microdilution was utilized to obtain the MICs. TK was performed in duplicate with samples taken 0, 4, 8, and 24 hours after initial inoculation. During each time point, samples were automatically spiral plated onto Mueller Hinton agar plates and incubated for 16-24 hours at 37 oC before colonies were enumerated to estimate bacterial density (CFU/mL). Antimicrobials tested included meropenem 16 μg/mL, cefepime 32 μg/mL, piperacillin/tazobactam 64/4 μg/mL, amikacin 4 μg/mL, plazomicin 4 μg/mL, and aztreonam/avibactam 32/4 μg/mL. Average bacterial density reduction after 24 hours was the outcome of interest. Meropenem and plazomicin alone achieved bactericidal or bacteriostatic activity in at least a single time-kill experiment for all isolates except for meropenem against one isolate. Aztreonam/avibactam and meropenem with either amikacin or plazomicin achieved bactericidal activity by 4 hours which sustained until 24 hours except for a single isolate in which meropenem/plazomicin only achieved bacteriostatic activity. These combinations were the most active with average bacterial density decreases of 3.86, 3.89, and 3.64 log10reductions, respectively. Cefepime or piperacillin/tazobactam combined with plazomicin minimally improved the average bacterial inocula reduction compared to plazomicin monotherapy. When combined with amikacin, cefepime and piperacillin/tazobactam achieved inconsistent bactericidal activity after 24 hours, though cefepime on average led to a bacterial reduction > 2 log10 CFU/mL lower than piperacillin/tazobactam. Against 8 clinical VIM-producing K. pneumoniae and E. cloacae, beta-lactam combination therapy achieved rapid and sustained bactericidal activity. Further investigation is necessary to rationally guide the use of these combination therapies against CRE. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2536. Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides and aztreonam/avibactam against 8 VIM-producing CRE
Treatment of infections caused by CRE often involves beta-lactam-containing combination therapy, either with a beta-lactamase inhibitor or an agent from a different antimicrobial class. We sought to investigate the activity of several beta-lactam combinations against 8 VIM-producing CRE cultured from patients at our academic medical center using a time-kill assay. Broth microdilution was utilized to obtain the MICs. TK was performed in duplicate with samples taken 0, 4, 8, and 24 hours after initial inoculation. During each time point, samples were automatically spiral plated onto Mueller Hinton agar plates and incubated for 16-24 hours at 37 oC before colonies were enumerated to estimate bacterial density (CFU/mL). Antimicrobials tested included meropenem 16 μg/mL, cefepime 32 μg/mL, piperacillin/tazobactam 64/4 μg/mL, amikacin 4 μg/mL, plazomicin 4 μg/mL, and aztreonam/avibactam 32/4 μg/mL. Average bacterial density reduction after 24 hours was the outcome of interest. Meropenem and plazomicin alone achieved bactericidal or bacteriostatic activity in at least a single time-kill experiment for all isolates except for meropenem against one isolate. Aztreonam/avibactam and meropenem with either amikacin or plazomicin achieved bactericidal activity by 4 hours which sustained until 24 hours except for a single isolate in which meropenem/plazomicin only achieved bacteriostatic activity. These combinations were the most active with average bacterial density decreases of 3.86, 3.89, and 3.64 log10reductions, respectively. Cefepime or piperacillin/tazobactam combined with plazomicin minimally improved the average bacterial inocula reduction compared to plazomicin monotherapy. When combined with amikacin, cefepime and piperacillin/tazobactam achieved inconsistent bactericidal activity after 24 hours, though cefepime on average led to a bacterial reduction > 2 log10 CFU/mL lower than piperacillin/tazobactam. Against 8 clinical VIM-producing K. pneumoniae and E. cloacae, beta-lactam combination therapy achieved rapid and sustained bactericidal activity. Further investigation is necessary to rationally guide the use of these combination therapies against CRE. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with standard microbiologic identification methods and concordance of ePlex® genotypic resistance mechanism detection and standard susceptibility testing. Secondary outcomes included panel specific performance and characterization of antimicrobial stewardship opportunities. This retrospective, single center study included patients with a positive blood culture from May 2020 – January 2021. Polymicrobial cultures were excluded. Identification concordance was evaluated between ePlex® and MALDI-TOF, BD Phoenix™, and biochemical tests. Resistance mechanism/phenotypic susceptibility concordance was evaluated between ePlex® and BD PhoenixTM/ETEST®. MecA was assessed via oxacillin resistance, vanA via vancomycin resistance, CTX-M via ceftriaxone resistance, and KPC via carbapenem resistance. Opportunities for antimicrobial stewardship were also quantified. The overall identification concordance rate in 1276 positive blood cultures was 98.2%, with rates of 98.5%, 98.1%, and 93.3% for Gram-positive, Gram-negative, and fungal isolates, respectively. In 381 staphylococcal isolates, concordance rates were 98.3% and 100% for the presence and absence of mecA. Both the presence and absence of vanA were 100% concordant in 63 enterococcal isolates. CTX-M and KPC were evaluated in 189 Enterobacterales. Concordance rates were 96.8% for the presence of CTX-M and 60% for the presence of KPC, demonstrating that 40% of carbapenem resistance was due to non-enzymatic mechanisms. Ceftriaxone and carbapenem susceptibility correlated with the absence of CTX-M and KPC, respectively, in 100% of cultures. A majority of ePlex results (69.5%) represented opportunities for potential antimicrobial stewardship intervention. High concordance rates between ePlex® and standard identification and susceptibility testing methods enable rapid antimicrobial optimization. Numerous opportunities for antimicrobial stewardship were identified based on ePlex® results. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with standard microbiologic identification methods and concordance of ePlex® genotypic resistance mechanism detection and standard susceptibility testing. Secondary outcomes included panel specific performance and characterization of antimicrobial stewardship opportunities. This retrospective, single center study included patients with a positive blood culture from May 2020 – January 2021. Polymicrobial cultures were excluded. Identification concordance was evaluated between ePlex® and MALDI-TOF, BD Phoenix™, and biochemical tests. Resistance mechanism/phenotypic susceptibility concordance was evaluated between ePlex® and BD PhoenixTM/ETEST®. MecA was assessed via oxacillin resistance, vanA via vancomycin resistance, CTX-M via ceftriaxone resistance, and KPC via carbapenem resistance. Opportunities for antimicrobial stewardship were also quantified. The overall identification concordance rate in 1276 positive blood cultures was 98.2%, with rates of 98.5%, 98.1%, and 93.3% for Gram-positive, Gram-negative, and fungal isolates, respectively. In 381 staphylococcal isolates, concordance rates were 98.3% and 100% for the presence and absence of mecA. Both the presence and absence of vanA were 100% concordant in 63 enterococcal isolates. CTX-M and KPC were evaluated in 189 Enterobacterales. Concordance rates were 96.8% for the presence of CTX-M and 60% for the presence of KPC, demonstrating that 40% of carbapenem resistance was due to non-enzymatic mechanisms. Ceftriaxone and carbapenem susceptibility correlated with the absence of CTX-M and KPC, respectively, in 100% of cultures. A majority of ePlex results (69.5%) represented opportunities for potential antimicrobial stewardship intervention. High concordance rates between ePlex® and standard identification and susceptibility testing methods enable rapid antimicrobial optimization. Numerous opportunities for antimicrobial stewardship were identified based on ePlex® results. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
716. Effect of Carbapenem-resistant vs. Carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
Carbapenem-resistant Enterobacterales (CRE) infections have been shown to lead to excess mortality in patients. To estimate the impact of CRE at an academic medical center not in an endemic area for CRE infections, we sought to compare them against patients having infections by carbapenem-susceptible Enterobacterales (CSE). This was a retrospective cohort study performed at UK Healthcare Medical Center which assessed admissions between January 1, 2010 – December 31, 2019. The index date was the first positive culture of E. coli, E. cloacae, K. aerogenes, K. oxytoca, and/or K. pneumoniae. Patients having a CRE culture on index were included in the exposure group, and those having all CSE cultures were included in the comparator group. Exclusion criteria were age < 18 years old, pregnancy, endocarditis, osteomyelitis, necrotizing fasciitis, or cystic fibrosis. Outcomes of interest were 14- and 30-day composite of all-cause mortality or discharge to hospice with follow-up beginning from the index culture. Relative risk (RR) and hazard ratio (HR) were utilized to compare outcomes and inverse probability of treatment weighting (IPTW) was used for statistical adjustment. Across the decade, 128 patients were included in the CRE group and 6,953 in the CSE group. IPTW-adjusted RR and HR [95% CI] of composite outcome were 1.11 [0.7, 1.74] and 0.98 [0.61, 1.57] after 14 days and 1.19 [0.8, 1.77] and 0.99 [0.65, 1.51] after 30 days, respectively. When utilizing an exposure definition of carbapenem non-susceptible Enterobacterales (CNSE), the RR and HR were 1.11 [0.79, 1.57] and 0.95 [0.66, 1.36] after 14 days and 1.25 [0.93, 1.68] and 1.02 [0.75, 1.4] after 30 days. When using the non-susceptible exposure and only including patients with bloodstream infections on index, the RR and HR were 1.50 [0.93, 2.43] and 1.42 [0.85, 2.36] after 14 days and 1.48 [0.96, 2.29] and 1.38 [0.85, 2.24] after 30 days. Although the composite outcomes between the CRE and CSE groups were not statistically significantly different, an increased risk appeared to exist in follow-up analysis. Continued efforts including observations across multiple institutions are needed to further characterize risks associated with CRE infections. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access716. Effect of Carbapenem-resistant vs. Carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
Carbapenem-resistant Enterobacterales (CRE) infections have been shown to lead to excess mortality in patients. To estimate the impact of CRE at an academic medical center not in an endemic area for CRE infections, we sought to compare them against patients having infections by carbapenem-susceptible Enterobacterales (CSE). This was a retrospective cohort study performed at UK Healthcare Medical Center which assessed admissions between January 1, 2010 – December 31, 2019. The index date was the first positive culture of E. coli, E. cloacae, K. aerogenes, K. oxytoca, and/or K. pneumoniae. Patients having a CRE culture on index were included in the exposure group, and those having all CSE cultures were included in the comparator group. Exclusion criteria were age < 18 years old, pregnancy, endocarditis, osteomyelitis, necrotizing fasciitis, or cystic fibrosis. Outcomes of interest were 14- and 30-day composite of all-cause mortality or discharge to hospice with follow-up beginning from the index culture. Relative risk (RR) and hazard ratio (HR) were utilized to compare outcomes and inverse probability of treatment weighting (IPTW) was used for statistical adjustment. Across the decade, 128 patients were included in the CRE group and 6,953 in the CSE group. IPTW-adjusted RR and HR [95% CI] of composite outcome were 1.11 [0.7, 1.74] and 0.98 [0.61, 1.57] after 14 days and 1.19 [0.8, 1.77] and 0.99 [0.65, 1.51] after 30 days, respectively. When utilizing an exposure definition of carbapenem non-susceptible Enterobacterales (CNSE), the RR and HR were 1.11 [0.79, 1.57] and 0.95 [0.66, 1.36] after 14 days and 1.25 [0.93, 1.68] and 1.02 [0.75, 1.4] after 30 days. When using the non-susceptible exposure and only including patients with bloodstream infections on index, the RR and HR were 1.50 [0.93, 2.43] and 1.42 [0.85, 2.36] after 14 days and 1.48 [0.96, 2.29] and 1.38 [0.85, 2.24] after 30 days. Although the composite outcomes between the CRE and CSE groups were not statistically significantly different, an increased risk appeared to exist in follow-up analysis. Continued efforts including observations across multiple institutions are needed to further characterize risks associated with CRE infections. All Authors: No reported disclosures
- 6 October 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (4) , 479-485
Time Above All Else: Pharmacodynamic Analysis of β‐Lactams in Critically Ill Patients
β-lactams are the most commonly utilized antibiotics in intensive care units (ICUs). As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure. The primary objective was to identify β-lactam regimens capable of achieving ≥90% cumulative fraction of response (CFR) against seven Gram-negative pathogens within four ICUs at our institution. Unit-specific MIC distribution data was utilized in combination with published pharmacokinetic parameters in critically ill patients to perform Monte Carlo simulations. The percentage of time for which the unbound concentration of antibiotic remained above the MIC (%ƒT>MIC) was utilized as the pharmacodynamic target: 70%ƒT>MIC for cefepime, 40%ƒT>MIC for meropenem, and 50%ƒT>MIC for piperacillin/tazobactam. Regimens were modeled to determine the likelihood of achieving ≥90% CFR. Overall, intermittently dosed cefepime, meropenem, and piperacillin/tazobactam failed to achieve ≥90% CFR for every organism. Cefepime 2g IB q8h failed to achieve ≥90% CFR for K. pneumoniae or E. cloacae despite susceptibility rates exceeding 90%. Piperacillin/tazobactam 4.5g PI q6h achieved P. aeruginosa and A. baumannii in every ICU. Meropenem 2g PI q8h and meropenem 2g PI q6h were the only regimens capable of achieving ≥90% CFR for P. aeruginosa in all units. Utilization of Monte Carlo simulations, with incorporation of local MIC distribution data, provides a mechanism to effectively predict optimal agent and dose selection within specific hospital systems, thereby enhancing PK/PD optimization and improving clinical efficacy. This article is protected by copyright. All rights reserved
- 6 October 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (4) , 479-485
Time Above All Else: Pharmacodynamic Analysis of β‐Lactams in Critically Ill Patients
β-lactams are the most commonly utilized antibiotics in intensive care units (ICUs). As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure. The primary objective was to identify β-lactam regimens capable of achieving ≥90% cumulative fraction of response (CFR) against seven Gram-negative pathogens within four ICUs at our institution. Unit-specific MIC distribution data was utilized in combination with published pharmacokinetic parameters in critically ill patients to perform Monte Carlo simulations. The percentage of time for which the unbound concentration of antibiotic remained above the MIC (%ƒT>MIC) was utilized as the pharmacodynamic target: 70%ƒT>MIC for cefepime, 40%ƒT>MIC for meropenem, and 50%ƒT>MIC for piperacillin/tazobactam. Regimens were modeled to determine the likelihood of achieving ≥90% CFR. Overall, intermittently dosed cefepime, meropenem, and piperacillin/tazobactam failed to achieve ≥90% CFR for every organism. Cefepime 2g IB q8h failed to achieve ≥90% CFR for K. pneumoniae or E. cloacae despite susceptibility rates exceeding 90%. Piperacillin/tazobactam 4.5g PI q6h achieved P. aeruginosa and A. baumannii in every ICU. Meropenem 2g PI q8h and meropenem 2g PI q6h were the only regimens capable of achieving ≥90% CFR for P. aeruginosa in all units. Utilization of Monte Carlo simulations, with incorporation of local MIC distribution data, provides a mechanism to effectively predict optimal agent and dose selection within specific hospital systems, thereby enhancing PK/PD optimization and improving clinical efficacy. This article is protected by copyright. All rights reserved
- 1 December 2020
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 56 (6) , 106178
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae
- 1 December 2020
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 56 (6) , 106178
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae
- Open Access
- 1 January 2020
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 7
Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance
To review the mechanism of action, mechanisms of resistance, in vitro activity, pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside. A PubMed search was performed from January 2006 to August 2019 using the following search terms: plazomicin and ACHN-490. Another search was conducted on clinicaltrials.gov for published clinical data. References from selected studies were also used to find additional literature. All English-language studies presenting original research (in vitro, in vivo, pharmacokinetic, and clinical) were evaluated. Plazomicin has in vitro activity against several multi-drug-resistant organisms, including carbapenem-resistant Enterobacteriaceae. It was Food and Drug Administration (FDA) approved to treat complicated urinary tract infections (cUTIs), including acute pyelonephritis, following phase II and III trials compared with levofloxacin and meropenem, respectively. Despite the FDA Black Box Warning for aminoglycoside class effects (nephrotoxicity, ototoxicity, neuromuscular blockade, and pregnancy risk), it exhibited a favorable safety profile with the most common adverse effects being decreased renal function (3.7%), diarrhea (2.3%), hypertension (2.3%), headache (1.3%), nausea (1.3%), vomiting (1.3%), and hypotension (1.0%) in the largest in-human trial. Plazomicin will likely be used in the treatment of multi-drug-resistant cUTIs or in combination to treat serious carbapenem-resistant Enterobacteriaceae infections. Plazomicin appears poised to help fill the need for new agents to treat infections caused by multi-drug-resistant Enterobacteriaceae.
- 1 January 2020
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 7
Open AccessPlazomicin: a new aminoglycoside in the fight against antimicrobial resistance
To review the mechanism of action, mechanisms of resistance, in vitro activity, pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside. A PubMed search was performed from January 2006 to August 2019 using the following search terms: plazomicin and ACHN-490. Another search was conducted on clinicaltrials.gov for published clinical data. References from selected studies were also used to find additional literature. All English-language studies presenting original research (in vitro, in vivo, pharmacokinetic, and clinical) were evaluated. Plazomicin has in vitro activity against several multi-drug-resistant organisms, including carbapenem-resistant Enterobacteriaceae. It was Food and Drug Administration (FDA) approved to treat complicated urinary tract infections (cUTIs), including acute pyelonephritis, following phase II and III trials compared with levofloxacin and meropenem, respectively. Despite the FDA Black Box Warning for aminoglycoside class effects (nephrotoxicity, ototoxicity, neuromuscular blockade, and pregnancy risk), it exhibited a favorable safety profile with the most common adverse effects being decreased renal function (3.7%), diarrhea (2.3%), hypertension (2.3%), headache (1.3%), nausea (1.3%), vomiting (1.3%), and hypotension (1.0%) in the largest in-human trial. Plazomicin will likely be used in the treatment of multi-drug-resistant cUTIs or in combination to treat serious carbapenem-resistant Enterobacteriaceae infections. Plazomicin appears poised to help fill the need for new agents to treat infections caused by multi-drug-resistant Enterobacteriaceae.